Regulatory professionals have complicated jobs with many types of demands; tight timelines, divisional overlap and complex project plans. It’s therefore critical that regulatory professionals be persuasive, engaging and influential within their companies and health...
The shift within the pharmaceutical industry from a risk-averse approach to overseeing clinical trials to a risk-based approach is “earthshaking”, a 2017 Avoca Group survey published on Outsourcing-Pharma.com states. A November 2016 guidance from the International...
Pearl IRB is proud to announce its recent reaccreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP). The Final Site Visit Report was reviewed by the AAHRPP Council on Accreditation during its December 2017 meeting. The...
Our office will be closed December 25th, 26th, 31st and also on January 1st for the holidays. There will not be a Pearl IRB board meeting on December 27th or January 3rd.. The week of January 8th, the normal IRB Board meeting schedule will resume. If you need to talk...
There are over 2,000 immunotherapy drugs currently in development. However, a meagre 5% of cancer patients partake in clinical trials, according to a PBS News Hour report. Consequently, America’s second leading cause of death, cancer, continues to claim more lives...
